Compare Live Nation Entertainment, Inc. (LYV) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Live Nation Entertainment, Inc. trades at $169.98 (market cap $39.91B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Live Nation Entertainment, Inc. is far larger — about 41× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LYV | MRVI | |
|---|---|---|
Market Cap | $39.91B | $972.90M |
Volume | 1,800,962 | 4,325,710 |
Sector | Media | Health |
52-Week High | $188.46 | $9.00 |
52-Week Low | $125.61 | $2.83 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $42.12B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $168.84, down 0.47% on the day, with a neutral technical signal. The stock shows strong analyst support with an 86.96% buy rating and a $208.64 consensus price target, implying significant upside. Recent Q2 2026 earnings beat expectations with EPS of $1.05 versus $0.66 expected, driven by robust fan attendance and record deferred revenue. However, valuation metrics remain elevated with a P/E of 117.49 and P/B of 484.76, while profitability is thin with a net income margin of 0.51%.
The outlook is cautiously optimistic given strong demand for live events and strategic expansions, but high debt levels, regulatory scrutiny, and execution risks pose challenges. Revenue growth is projected to reach $26.3 billion in 2026, though net profit margins are expected to compress to 0.51%. Investors should weigh the bullish analyst sentiment against the stock's rich valuation and operational headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
